Família ABC Arquivos Brasileiros de Cardiologia International Journal of Cardiovascular Sciences ABC Heart Failure & Cardiomyopathy ABC Imagem Cardiovascular
Português English
Família ABC
Português English
  • Sobre
    • Sobre a Família ABC
    • Regimento Interno
    • Conselho Editorial
    • Sociedade Brasileira de Cardiologia (SBC)
  • Edições
  • Diretrizes da SBC
  • Conteúdos
    • Vídeos
    • Podcasts
    • Notícias
  • Sobre
    • Sobre a Família ABC
    • Regimento Interno
    • Conselho Editorial
    • Sociedade Brasileira de Cardiologia (SBC)
  • Edições
  • Diretrizes da SBC
  • Conteúdos
    • Vídeos
    • Podcasts
    • Notícias

Família ABC

  • Família ABC
  • Arquivos Brasileiros de Cardiologia
  • International Journal of Cardiovascular Sciences
  • ABC Heart Failure & Cardiomyopathy
  • ABC Imagem Cardiovascular
Buscar em

Nenhum conteúdo encontrado.

Revistas
Ordenação
Tipos de artigo
Outros

  1. Início
  2. Palavra-chave: Therapeutics
IJCS
Editorial

Cardiac Myosin Inhibitors in Patients with Hypertrophic Cardiomyopathy

Marcelo Imbroinise Bittencourt et al. Ricardo Mourilhe-Rocha

In recent years, we have witnessed a significant shift in the management of symptomatic Hypertrophic Cardiomyopathy (HCM). For decades, treatment relied on medications that provided hemodynamic support without directly addressing sarcomeric hypercontractility, the primary pathophysiological driver of the disease. The emergence of Cardiac Myosin Inhibitors (CMIs), particularly mavacamten and aficamten, has transformed this landscape., In an article published in this issue of the International Journal of Cardiovascular Sciences, Fogaça PHT et al. present an updated systematic review and meta-analysis that reinforces the efficacy of this class of medications while providing important insights into their effects in both obstructive and non-obstructive HCM.

The study pooled data from six randomized controlled trials. Five included patients with obstructive HCM, whereas one – the MAVERICK-HCM trial – included patients with non-obstructive HCM.,,- The inclusion of non-obstructive patients represents a distinctive aspect of this analysis, as the benefits of CMIs in the absence of left ventricular outflow tract (LVOT) obstruction remain less well established.

[…]

  • Cardiac Myosins
  • Hypertrophic Cardiomyopathy
  • Therapeutics
Ler artigo completo
Creative Commons Attribution (CC BY) Creative Commons license
21/08/2026 DOI: 10.36660/ijcs.20260134 Visualizações 3
IJCS
Review Article

Cardiac Amyloidosis in Women: An Underappreciated Diagnosis

Larissa Neto Espíndola et al. Gláucia Maria Moraes de Oliveira Cláudia Maria Vilas Freire Marildes Luiza de Castro Maria Cristina Costa de Almeida

Abstract

Cardiac amyloidosis (CA) is an infiltrative cardiomyopathy that affects the heart mostly in two forms: immunoglobulin light chain amyloidosis (AL-CM) and transthyretin amyloidosis.

Transthyretin amyloid cardiomyopathy (ATTR-CM) predominantly affects the elderly population, mainly men (about 70-80%), and usually manifests with symptoms of heart failure (HF).

Despite technological advances in medicine, CA is still an underdiagnosed condition, especially in women, partly due to the known male predominance and high level of suspicion required for diagnosis. It is important to remember that amyloidosis is a systemic disease with a heterogeneous and non-specific presentation. It’s worth paying attention to the patient’s medical history and red flags in clinical and diagnostic tests (electrocardiogram [ECG], echocardiogram [ECHO], cardiac magnetic resonance [CMR]).

Accurate and timely diagnosis is crucial for appropriate management and prognosis.

So far, the under-representation of women in clinical trials may have also limited the evidence on sex-specific diagnosis, and outcomes.

  • Amyloidosis
  • Diagnosis
  • Prognosis
  • Therapeutics
  • Women
Ler artigo completo
Creative Commons Attribution (CC BY) Creative Commons license
26/08/2024 DOI: 10.36660/ijcs.20240088 Visualizações 1
IJCS
Review Article

Bothrops Moojeni Snake Venom: A Source of Potential Therapeutic Agents Against Hemostatic Disorders

Natália Barreira Silva et al. Edigar Henrique Vaz Dias Júnia de Oliveira Costa Carla Cristine Neves Mamede

Abstract

Hemostasis is a complex set of biological processes responsible for blood fluidity within normal vessels and for the physiological interruption of bleeding in cases of vascular injury. Bothrops moojeni snake venom is rich in bioactive compounds of pharmacological and clinical interest since its protein components are capable of interfering with many points of the hemostatic process. Here, we present the B. moojeni venom proteins that affect hemostasis and discuss their pharmacological and clinical potential. This systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) protocol. Data were obtained from the CAPES Journal Portal database, using the terms “Bothrops” AND “hemostasis”, in a search for scientific articles made available in the last 20 years. Many components isolated from B. moojeni snake venom are characterized for their effect on hemostasis and possible application in the diagnosis and treatment of hemostatic disorders.

  • Hemostasis
  • Snake venoms
  • Therapeutics
Ler artigo completo
Creative Commons Attribution (CC BY) Creative Commons license
04/03/2024 DOI: 10.36660/ijcs.20220075

Como citar este artigo

EndNote RIS

Formato de Documento Eletrônico (Vancouver)

Bittencourt MI, Mourilhe-Rocha R. Cardiac Myosin Inhibitors in Patients with Hypertrophic Cardiomyopathy. International Journal of Cardiovascular Sciences 2026;39:e20260134.

Formato de Documento Eletrônico (ABNT)

Bittencourt, Marcelo Imbroinise; Mourilhe-Rocha, Ricardo. Cardiac Myosin Inhibitors in Patients with Hypertrophic Cardiomyopathy. International Journal of Cardiovascular Sciences, v. 39, e20260134, ago. 2026.

Formato de Documento Eletrônico (APA)

Bittencourt, M. I., & Mourilhe-Rocha, R. (2026). Cardiac Myosin Inhibitors in Patients with Hypertrophic Cardiomyopathy. International Journal of Cardiovascular Sciences, 39, e20260134.

Formato de Documento Eletrônico (ISO)

Bittencourt, Marcelo Imbroinise and Mourilhe-Rocha, Ricardo. Cardiac Myosin Inhibitors in Patients with Hypertrophic Cardiomyopathy. International Journal of Cardiovascular Sciences [online]. 2026, vol. 39, [citado 2026-10-14], e20260134. Disponível em: <https://journals.cardiol.br/article/cardiac-myosin-inhibitors-in-patients-with-hypertrophic-cardiomyopathy-2/>. ISSN 2359-4802

EndNote RIS

Formato de Documento Eletrônico (Vancouver)

Espíndola LN, Oliveira GMM, Freire CMV, Castro ML, Almeida MCC. Cardiac Amyloidosis in Women: An Underappreciated Diagnosis. International Journal of Cardiovascular Sciences 2024;37:e20240088.

Formato de Documento Eletrônico (ABNT)

Espíndola, Larissa Neto; Oliveira, Gláucia Maria Moraes de; Freire, Cláudia Maria Vilas; Castro, Marildes Luiza de; Almeida, Maria Cristina Costa de. Cardiac Amyloidosis in Women: An Underappreciated Diagnosis. International Journal of Cardiovascular Sciences, v. 37, e20240088, ago. 2024.

Formato de Documento Eletrônico (APA)

Espíndola, L. N., Oliveira, G. M. M. , Freire, C. M. V., Castro, M. L. , & Almeida, M. C. C. (2024). Cardiac Amyloidosis in Women: An Underappreciated Diagnosis. International Journal of Cardiovascular Sciences, 37, e20240088.

Formato de Documento Eletrônico (ISO)

Espíndola, Larissa Neto and Oliveira, Gláucia Maria Moraes de and Freire, Cláudia Maria Vilas and Castro, Marildes Luiza de and Almeida, Maria Cristina Costa de. Cardiac Amyloidosis in Women: An Underappreciated Diagnosis. International Journal of Cardiovascular Sciences [online]. 2024, vol. 37, [citado 2026-10-14], e20240088. Disponível em: <https://journals.cardiol.br/article/cardiac-amyloidosis-in-women-an-underappreciated-diagnosis-2/>. ISSN 2359-4802

EndNote RIS

Formato de Documento Eletrônico (Vancouver)

Silva NB, Dias EHV, Costa JO, Mamede CCN. Bothrops Moojeni Snake Venom: A Source of Potential Therapeutic Agents Against Hemostatic Disorders. International Journal of Cardiovascular Sciences 2024;37:e20220075.

Formato de Documento Eletrônico (ABNT)

Silva, Natália Barreira; Dias, Edigar Henrique Vaz; Costa, Júnia de Oliveira; Mamede, Carla Cristine Neves. Bothrops Moojeni Snake Venom: A Source of Potential Therapeutic Agents Against Hemostatic Disorders. International Journal of Cardiovascular Sciences, v. 37, e20220075, mar. 2024.

Formato de Documento Eletrônico (APA)

Silva, N. B., Dias, E. H. V., Costa, J. O., & Mamede, C. C. N. (2024). Bothrops Moojeni Snake Venom: A Source of Potential Therapeutic Agents Against Hemostatic Disorders. International Journal of Cardiovascular Sciences, 37, e20220075.

Formato de Documento Eletrônico (ISO)

Silva, Natália Barreira and Dias, Edigar Henrique Vaz and Costa, Júnia de Oliveira and Mamede, Carla Cristine Neves. Bothrops Moojeni Snake Venom: A Source of Potential Therapeutic Agents Against Hemostatic Disorders. International Journal of Cardiovascular Sciences [online]. 2024, vol. 37, [citado 2026-10-14], e20220075. Disponível em: <https://journals.cardiol.br/article/bothrops-moojeni-snake-venom-a-source-of-potential-therapeutic-agents-against-hemostatic-disorders-2/>. ISSN 2359-4802

  • Sobre a Família ABC
  • Regimento Interno
  • Conselho Editorial
  • Sociedade Brasileira de Cardiologia (SBC)

Edições

Diretrizes da SBC

  • Vídeos
  • Podcasts
  • Notícias